The Clinical Significance of Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors.

is an oncogene expressed as a long non-coding RNA. However, our team previously reported that the gene also encodes a micropeptide, CRNDEP. The amino acid sequence of CRNDEP has recently been revealed by other researchers, too.

A Multi-Faceted Analysis Showing Transcripts and a Recently Confirmed Micropeptide as Important Players in Ovarian Carcinogenesis.

is considered an oncogene expressed as long non-coding RNA. Our previous paper is the only one reporting as a micropeptide-coding gene. The amino acid sequence of this micropeptide (CRNDEP) has recently been confirmed by other researchers.

PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.

Considering the vast biological diversity and high mortality rate in high-grade ovarian cancers, identification of novel biomarkers, enabling precise diagnosis and effective, less aggravating treatment, is of paramount importance. Based on scientific literature data, we selected 80 cancer-related genes and evaluated their mRNA expression in 70 high-grade serous ovarian cancer (HGSOC) samples by Real-Time qPCR. The results were validated in an independent Northern American cohort of 85 HGSOC patients with publicly available NGS RNA-seq data.